Mymetics Corporation
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MYMX research report →
Price Chart
About the company
Mymetics Corporation is a Swiss biotechnology company dedicated to the research and development of vaccines aimed at preventing infectious and debilitating diseases. Its robust pipeline features several promising vaccine candidates, including those for HIV-1/AIDS, COVID-19, intranasal influenza, respiratory syncytial virus (RSV), malaria, and chikungunya. The company actively collaborates with leading institutions such as the Texas Biomedical Research Institute, the PATH Malaria Vaccine Initiative, and the National Institute of Allergy and Infectious Diseases' Laboratory of Malaria Immunology and Vaccinology, focusing on the development and production of virosome-based vaccine formulations for a malaria transmission-blocking agent.
- CEO
- Ronald Kempers
- IPO
- 1999
- Employees
- 2
- HQ
- Epalinges, VD, CH
Get TickerSpark's AI analysis on MYMX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $46
- P/E
- -0.02
- PEG
- 0.00
- P/S
- 0.01
- P/B
- -0.00
- EV/EBITDA
- -36.02
- Div Yield
- 0.00%
- Gross Margin
- -47966.67%
- Op Margin
- -58166.67%
- Net Margin
- -160166.67%
- ROE
- 7.69%
- ROIC
- -24.57%
Latest fiscal year · YoY change
- Revenue
- $3.00K+0.0%
- Gross Profit
- $-1,439,000-48.0%
- Op Income
- $-1,745,000
- Net Income
- $-4,805,000-1.6%
- EPS
- $-0.02+32.8%
- OCF Growth
- +0.6%
- FCF Growth
- +1.1%
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 2.34
- RSI (14)
- 50
- Avg Volume
- 90
No earnings-call transcripts are available for MYMX yet.
- Free Float
- 48.5%
- Shares Outstanding
- 151.88K
- Float Shares
- 73.58K
of shares held by institutions
1 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jan 16, 23 | Ruegg Marcel B. | other | 0 |
| Apr 9, 15 | KEMPERS Ronald Hugo Gerard | other | 5,000,000 |
| Mar 23, 12 | Burkhard Ulrich | other | 0 |
| Jan 31, 06 | Round Enterprises, Ltd. | other | 0 |
| Jan 31, 06 | Round Enterprises, Ltd. | other | 0 |
| Oct 4, 13 | Fleury Sylvain | other | 800,000 |
| Dec 31, 09 | Fleury Sylvain | other | 350,000 |
| Jun 18, 07 | Fleury Sylvain | other | 0 |
| Jun 17, 10 | Stegmann Antonius Johannes | other | 4,000,000 |
| Jun 17, 10 | Stegmann Antonius Johannes | other | 150,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our MYMX coverage
Recent articles, reports, and earnings notes.
No research on MYMX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate MYMX report →